These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 20651033)

  • 1. Genome-wide catalogue of chromosomal aberrations in barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis.
    Gu J; Ajani JA; Hawk ET; Ye Y; Lee JH; Bhutani MS; Hofstetter WL; Swisher SG; Wang KK; Wu X
    Cancer Prev Res (Phila); 2010 Sep; 3(9):1176-86. PubMed ID: 20651033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma.
    Akagi T; Ito T; Kato M; Jin Z; Cheng Y; Kan T; Yamamoto G; Olaru A; Kawamata N; Boult J; Soukiasian HJ; Miller CW; Ogawa S; Meltzer SJ; Koeffler HP
    Int J Cancer; 2009 Nov; 125(10):2349-59. PubMed ID: 19670330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
    Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
    Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-wide copy number analysis in esophageal adenocarcinoma using high-density single-nucleotide polymorphism arrays.
    Nancarrow DJ; Handoko HY; Smithers BM; Gotley DC; Drew PA; Watson DI; Clouston AD; Hayward NK; Whiteman DC
    Cancer Res; 2008 Jun; 68(11):4163-72. PubMed ID: 18519675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression.
    Li X; Galipeau PC; Sanchez CA; Blount PL; Maley CC; Arnaudo J; Peiffer DA; Pokholok D; Gunderson KL; Reid BJ
    Cancer Prev Res (Phila); 2008 Nov; 1(6):413-23. PubMed ID: 19138988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's esophagus.
    Streppel MM; Lata S; DelaBastide M; Montgomery EA; Wang JS; Canto MI; Macgregor-Das AM; Pai S; Morsink FH; Offerhaus GJ; Antoniou E; Maitra A; McCombie WR
    Oncogene; 2014 Jan; 33(3):347-57. PubMed ID: 23318448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus.
    Doak SH; Jenkins GJ; Parry EM; D'Souza FR; Griffiths AP; Toffazal N; Shah V; Baxter JN; Parry JM
    Gut; 2003 May; 52(5):623-8. PubMed ID: 12692043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence.
    Walch AK; Zitzelsberger HF; Bruch J; Keller G; Angermeier D; Aubele MM; Mueller J; Stein H; Braselmann H; Siewert JR; Höfler H; Werner M
    Am J Pathol; 2000 Feb; 156(2):555-66. PubMed ID: 10666385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genes of the interleukin-18 pathway are associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma.
    Babar M; Ryan AW; Anderson LA; Segurado R; Turner G; Murray LJ; Murphy SJ; Johnston BT; Comber H; Reynolds JV; McManus R
    Am J Gastroenterol; 2012 Sep; 107(9):1331-41. PubMed ID: 22664470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Massively Parallel Sequencing of Esophageal Brushings Enables an Aneuploidy-Based Classification of Patients With Barrett's Esophagus.
    Douville C; Moinova HR; Thota PN; Shaheen NJ; Iyer PG; Canto MI; Wang JS; Dumot JA; Faulx A; Kinzler KW; Papadopoulos N; Vogelstein B; Markowitz SD; Bettegowda C; Willis JE; Chak A
    Gastroenterology; 2021 May; 160(6):2043-2054.e2. PubMed ID: 33493502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses.
    Kaz AM; Wong CJ; Luo Y; Virgin JB; Washington MK; Willis JE; Leidner RS; Chak A; Grady WM
    Epigenetics; 2011 Dec; 6(12):1403-12. PubMed ID: 22139570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic changes in microRNA expression profiles reflect progression of Barrett's esophagus to esophageal adenocarcinoma.
    Slaby O; Srovnal J; Radova L; Gregar J; Juracek J; Luzna P; Svoboda M; Hajduch M; Ehrmann J
    Carcinogenesis; 2015 May; 36(5):521-7. PubMed ID: 25784377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorescence in situ hybridization mapping of esophagectomy specimens from patients with Barrett's esophagus with high-grade dysplasia or adenocarcinoma.
    Brankley SM; Fritcher EG; Smyrk TC; Keeney ME; Campion MB; Voss JS; Clayton AC; Wang KK; Lutzke LS; Kipp BR; Halling KC
    Hum Pathol; 2012 Feb; 43(2):172-9. PubMed ID: 21820152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic alterations in malignant transformation of Barrett's esophagus.
    Riegman PH; Vissers KJ; Alers JC; Geelen E; Hop WC; Tilanus HW; van Dekken H
    Cancer Res; 2001 Apr; 61(7):3164-70. PubMed ID: 11306503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis.
    Leidner RS; Ravi L; Leahy P; Chen Y; Bednarchik B; Streppel M; Canto M; Wang JS; Maitra A; Willis J; Markowitz SD; Barnholtz-Sloan J; Adams MD; Chak A; Guda K
    Genes Chromosomes Cancer; 2012 May; 51(5):473-9. PubMed ID: 22302717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Oncogene amplification and genetic heterogeneity in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett esophagus].
    Walch A; Bink K; Hutzler P; Zitzelsberger H; Braselmann H; Aubele M; Höfler H; Werner M
    Verh Dtsch Ges Pathol; 2001; 85():257-63. PubMed ID: 11894407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent confirmed low-grade dysplasia in Barrett's esophagus is a risk factor for progression to high-grade dysplasia and adenocarcinoma in a US Veterans cohort.
    Song KY; Henn AJ; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ
    Dis Esophagus; 2020 Mar; 33(2):. PubMed ID: 31274147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
    Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.